pegylated liposomal doxorubicin + trastuzumab + paclitaxel

This is a combination regimen consisting of three agents: pegylated liposomal doxorubicin (PLD), trastuzumab, and paclitaxel. - **Pegylated liposomal doxorubicin** is a formulation of the anthracycline antibiotic doxorubicin encapsulated in long-circulating PEG-coated liposomes. This modification prolongs circulation time and reduces cardiotoxicity compared to conventional doxorubicin[4][5][9]. It acts primarily by intercalating DNA and inhibiting topoisomerase II, leading to inhibition of DNA replication and cell death. - **Trastuzumab** is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/ERBB2). It inhibits HER2-mediated signaling pathways involved in cell proliferation and survival. - **Paclitaxel** is a microtubule-stabilizing agent that promotes tubulin polymerization, preventing normal mitotic spindle function during cell division[8][10]. This combination has been studied primarily in HER2-positive breast cancer settings—both metastatic and neoadjuvant—where it aims to maximize antitumor efficacy while minimizing cardiac toxicity associated with traditional anthracyclines[1][2].

Brand names

None (no unique brand name for this specific combination; individual components have brand names such as Caelyx for pegylated liposomal doxorubicin, Herceptin for trastuzumab, and Taxol for paclitaxel)

Other names

PLD + trastuzumab + paclitaxelCaelyx + Herceptin + Taxol (component brand names)